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Kaposi’ssarcoma(KS)isavasculartumorfrequentlyoccurringinHumanImmunodeﬁciencyVirus-(HIV-)1-infectedindividuals.
Our previous work indicated that the angiogenic ﬁbroblast growth factor (FGF)-2 and the Tat protein of HIV-1, both expressed
in KS lesions of HIV-infected patients, synergize at inducing angioproliferative, KS-like lesions in mice. Here we show that the
development of angioproliferative lesions promoted in mice by combined Tat and FGF-2 associates with an increase in the levels
of expression of the antiapoptotic Bcl-2 protein. Upregulation of Bcl-2 expression by combined FGF-2 and Tat occurs also in vitro,
and this protects human primary endothelial cells from programmed cell death. As Bcl-2 is expressed in human KS lesions in a
fashionparallelingtheprogressionofthedisease,theseﬁndingssuggestamolecularmechanismbywhichTatandFGF-2cooperate
in KS maintenance and progression in HIV-infected individuals.
1.Introduction
KSarisesasmultiplepatch,plaque,ornodularlesions,which
are generally located on the skin or mucosas but can also
involve visceral organs (reviewed in [1]).
Early-stage KS lesions resemble an inﬂammatory, granu-
lation-type reaction, and they are characterized by abnormal
angiogenesis, leukocyte inﬁltration, endothelial cell activa-
tion, edema and by the proliferation of endothelial-like,
spindle-shapedcellswhichareconsideredtobetheKStumor
cells (KS cells) [1].
T h ed e v e l o p m e n to fK Sl e s i o n si st r i g g e r e db yi n ﬂ a m m a -
torymediatorsandgrowthfactors[1],whoseproductioncan
be induced or enhanced by the human herpesvirus-8 (HHV-
8), a viral agent infecting nearly all KS patients (reviewed in
[2]).
AmongthegrowthfactorsexpressedinKSlesions,FGF-2
is key for KS development. Speciﬁcally, upon its production
by KS cells or inﬁltrating leukocytes, FGF-2 stimulates the
locomotion and growth of both endothelial and KS cells
by paracrine and autocrine mechanisms, respectively [1].
Consistently,FGF-2candirectlypromotethedevelopmentof
KS-like lesions in vivo [3, 4], and it mediates the formation
of angioproliferative lesions induced by KS cell injection in
nude mice [5].
Despite rare and slowly progressive in general popula-
tion,KSbecomesfrequentandaggressiveinHIV-infectedin-
dividuals (Acquired Immune Deﬁciency Syndrome- [AIDS-]
associated KS) [1].
In this regard, previous results indicated that the Tat
protein of HIV-1 can act as a progression factor in AIDS-KS.
In particular, Tat, a transactivator of HIV-1 gene expression2 International Journal of Vascular Medicine
which is essential for virus replication, is released by HIV-1
acutely infected T cells (reviewed in [6]). By engaging cell
surface receptors belonging to the integrin family, extra-
cellular Tat induces endothelial or KS cell locomotion and
adhesion [6]. At the same time, Tat competes FGF-2 binding
to the heparan-sulphate proteoglycans of the cell surface and
extracellular matrix (ECM) [7]. In doing so, Tat can retrieve
sequestered FGF-2 into a soluble, biologically active form
which, in turn, promotes endothelial or KS cell growth [7].
While early-stage KS lesions have a polyclonal nature and
may regress, late nodular KS lesions can evolve into a true
sarcoma [1]. Noteworthy, at this stage of disease progression,
KS lesions undergo a rapid growth in the presence of a low
mitotic index [8]. This suggested that vascular cell survival
could be prevalent in KS maintenance and progression.
In this context, the protein levels of Bcl-2, a potent
antagonistofprogrammedcelldeath(apoptosis),werefound
to be increased in late-stage, as compared to early-stage,
lesions from all forms of KS [8–12]. Coexpression of Bcl-2
and endothelial cell markers [9, 10] indicates that Bcl-2
is upregulated in activated endothelial cells lining the newly
formed, abnormal blood vessels characterizing KS lesions.
Consistently, Bcl-2 up-regulation is associated with the
reduction or absence of endothelial cell apoptosis [8, 9].
At the present time, however, little or nothing is known
about the mechanisms of Bcl-2 induction in KS.
Since either Tat or FGF-2 has been shown to modulate
Bcl-2 expression by a wide variety of cell types [13–21],
herein we evaluated the eﬀects of FGF-2 and Tat, alone
or combined, on Bcl-2 expression in animal and in vitro
experimental models previously employed to study AIDS-KS
pathogenesis.
2.MaterialsandMethods
2.1.Reagents. RecombinantHIV-1Tatprotein(fromtheIIIB
isolate) was obtained, puriﬁed, tested for biological activity,
and handled as previously described [22]. Human recom-
binant FGF-2 was purchased from Roche Molecular Bio-
chemicals (Indianapolis, IN). Bovine serum albumin (BSA,
fraction V), heparin (sodium salt, from porcine intestinal
mucosa), gelatin (denatured collagen I, from bovine skin),
andthechemicalsemployedforproteinextractionwerefrom
S i g m a( S t .L o u i s ,M O ) .M a t r i g e l ,ar e c o n s t i t u t e db a s e m e n t
membrane, and endothelial cell growth supplement (ECGS)
were obtained from BD Bioscience (Bedford, MA). The
phosphatebuﬀeredsaline(PBS)solution,RPMI1640growth
medium, and its supplements were from Invitrogen (Paisley,
Scotland, UK).
2.2. Animal Studies. Recombinant FGF-2 and/or Tat protein
(1μga n d1 0 μg, resp.) were suspended in 0.2mL of PBS-
0.1% BSA, mixed with an equal volume of Matrigel and
then injected subcutaneously into the lower back of Balb-c
nu/nu female mice (4–6-week old, Charles River Breeding
Laboratories, Calco, Italy), as previously described [3, 4].
Control animals were inoculated with the same volume
of Matrigel and the buﬀer (PBS-0.1% BSA) employed to
suspend FGF-2 or Tat. Seven days later, mice were sacriﬁced,
and, at this time, the sites of injection were evaluated for the
presence of macroscopic lesions [3, 4]. Tissue samples were
taken and ﬁxed in formalin or frozen in OCT compound
(Miles Laboratories, Naperville, IL). Slides obtained from
formalin-ﬁxed paraﬃn-embedded blocks were examined at
the microscope after hematoxylin-eosin staining. Frozen
tissue sections were ﬁxed in acetone and stained with
0.4μg/mL of anti-Bcl-2 rabbit polyclonal antibody (Santa
CruzBiotechnology,SantaCruz,CA)bytheperoxidase-anti-
peroxidase method (Dako) [3, 4]. The percentage of positive
cells was determined from the mean of 5 high-power ﬁelds
(40X magniﬁcation) and expressed as the mean (minimum
and maximal range) of values obtained. The care and use
of mice were in accordance with the European Community
guidelines.
2.3. Cell Cultures. Human umbilical vein endothelial cells
(HUVECs) were obtained from Lonza (Verviers, Belgium),
seeded on surfaces precoated with gelatin, and cultured in
RPMI 1640 medium supplemented with 15% fetal bovine
serum (FBS), sodium pyruvate, L-glutamine, MEM essential
and nonessential amino acids, heparin (1μg/mL), and ECGS
(45μg/mL). Experiments were performed in the absence of
ECGS or heparin.
2.4. Western Blot Analysis. At the end of each experiment,
HUVECs were washed in ice-cold PBS, scraped oﬀ the
ﬂask, and lysed in 50nM Tris pH 7.5, 1mM phenyl-
methylsulfonyl ﬂuoride (PMSF), 2mM EGTA, 10mM DTT,
5μg/mL aprotinin, 200μg/mL leupeptin, and 0.15% triton
X 100. The protein content in the cell lysates was assayed
with the Bradford reagent (Bio-Rad, Hercules,CA). Eight
μg of proteins from each experimental condition were
subjected to 12% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis followed by transfer onto nitrocellulose
membrane (Amersham Pharmacia Biotech, Little Chalfont,
Buckinghamshire,UK).Filterswererinsedinblockingbuﬀer
(5% nonfat dry milk, 0.1% Tween-20 PBS), probed with
anti-Bcl-2 monoclonal antibodies (2μg/mL, Santa Cruz),
incubatedwithhorseradishperoxidase-conjugatedgoatanti-
mouse secondary antibodies (Amersham), and developed
with the use of the enhanced chemiluminescence (ECL)
method (Amersham). Intensity of the Bcl-2-speciﬁc band
was quantiﬁed by densitometry, using an Imaging Den-
sitometer GS-700 and a Multi-Analyst software (Bio-Rad).
To verify equal loading of protein in each lane, blots were
reprobed with anti-β actin monoclonal antibodies (Sigma).
2.5. Detection of Apoptosis. HUVECs were seeded on
plates coated with gelatin or with 10μg/mL of poly-2-
hydroxymethyl-methacrylate[poly(HEMA)][23].Cellswere
exposed to FGF-2, Tat, or their suspension buﬀer and then
collected. The entity of cell death was determined by using
two diﬀerent assays.
The ﬁrst was the Programmed Cell Death ELISA
kit (Roche) which measures the amount of nucleosomes
released in the cytoplasm of dying cells. Brieﬂy, HUVECsInternational Journal of Vascular Medicine 3
(a) (b) (c)
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(g) (h)
Figure 1: Induction of Bcl-2 expression in mice by FGF-2 and Tat. Mice were injected with 1μg of FGF-2 and/or 10μg of Tat, as described
in Section 2. After 7 days tissue samples were taken at the injection sites and processed for histological examination by hematoxylin-eosin
staining (left panels, 40X magniﬁcation). Tissue sections from 12 animals per group were stained with anti-Bcl-2 antibody (right panels, 40X
magniﬁcation). Induction of KS-like lesions promoted by 1μg FGF-2 (a) was associated with Bcl-2 protein expression (b). The simultaneous
inoculation of 1μg FGF-2 and 10μg Tat further increased both lesion development (c) and Bcl-2 expression (d). The inoculation of 10μg
Tat alone induced only limited histological alterations (e) and no Bcl-2 protein expression (f) at the injection sites. Protein suspension buﬀer
(PBS-0.1% BSA) did not promote lesion development (g), nor Bcl-2 protein expression (h). Arrows point at some representative spindle
cells of KS-like lesions.
were lysed, and the cytoplasmic fraction was recovered after
centrifugation, and nucleosomes assayed as indicated by the
manufacturer. Each sample was tested in duplicate.
The second method was the terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling (TUNEL)
assay. Brieﬂy, HUVECs were spun on slides by cytospin,
ﬁxed in 4% paraformaldehyde, and the DNA strand breaks
of apoptotic cells were identiﬁed in situ by TUNEL kit
(Roche), according to the manufacturer’s instructions. Flu-
oresceinated nucleotides incorporated in polymers by the
terminal deoxynucleotidyl transferase-based enzymatic reac-
tion were detected by immuno-histochemical staining using
a mouse antiﬂuorescein isothiocyanate (FITC) monoclonal
antibody and the alkaline phosphatase-anti-alkaline phos-
phatase method (Dako) [3]. The percentage of positive,
apoptotic cells was determined from the mean of 4 high-
power ﬁelds.
2.6. Reverse Transcriptase-Polymerase Chain Reaction (RT-
PCR). Total RNA was extracted from HUVECs with the4 International Journal of Vascular Medicine
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Figure 2: Induction of Bcl-2 protein expression by FGF-2 and/or
Tat in human primary endothelial cells. HUVECs were cultured in
the presence of Tat (10ng/mL) and/or FGF-2 (1ng/mL). HUVECs
treated with the protein suspension buﬀer (PBS-0.1% BSA) were
usedascontrols.After24hoursofculture,HUVECswerelysed,and
equal amounts of total proteins were electrophoresed and analysed
by Western blotting using monoclonal antibodies directed against
human Bcl-2. Blots were reprobed with anti-β actin monoclonal
antibodies to verify equal loading of protein in each lane. In the
upper panel a representative Western blot for Bcl-2 protein is
shown. In the lower panel is its densitometric analysis, which is
presented as the Bcl-2 to β actin ratio. Repeated experiments (two)
gave similar results.
RNA assay Mini kit (Qiagen, Hilden, Germany) and
further puriﬁed by three-round digestion with pancre-
atic DNAse I (10IU/sample). Puriﬁed RNA (0.5μg) was
retrotranscribed with the reverse transcription system kit
(Promega, Madison, WI, USA) by incubating the reac-
tions with hexanucleotide random primers for 10min at
room temperature, 30min at 42◦C, and 30min at 53◦C.
After heat inactivation of the RT reaction, each sample
was subjected to a low (pre-plateau) number of cycles
of PCR (28 to 30) for β-actin with primer BA-1 [5 -
CATGTGCAAGGCCGGCTTCG-3 , nucleotide (nt) 1137 to
1156], located in the ﬁrst exon of the human β-actin gene,
and primer BA-4 (5 -GAAGGTGTGGTGCCAGATTT-3 ,n t
1475 to 1494) designed in the second exon of the gene (nt
enumeration as in GenBank M10277). These primers yield a
226bp cDNA amplicon; contaminant DNA is revealed by the
appearance of a 357bp genomic amplicon. The amount of
cDNA to be used for Bcl-2 PCR was determined after cDNA
normalization by pre-plateau β-actin PCR. The normalized
samples were then subjected to 35 cycles of PCR for Bcl-
2. Bcl-2 primers were 5 -TCGCCCTGGTGGACAACA-3  (nt
1957 to 1975) and 5 -TGACTTCACTTGTGGCTCAGA-3 
(nt 2183 to 2163) (nt enumeration as in GenBank M13994).
Conditions for Bcl-2 ampliﬁcation were as follows: 4min
at 94◦C, followed by 35 cycles of denaturation at 94◦Cf o r
1.5min,annealingat58◦Cfor1.5min,andextensionat72 ◦C
for 2min. Negative control reactions lacking DNA template
were always performed in parallel to control for sample to
sample contamination.
PCR-ampliﬁed products were separated onto a 1.8%
agarose gel, blotted on nylon membrane, and hybridized
to a 32 [P]-labeled oligonucleotide probe internal to the
amplicon by standard techniques. After extensive washing,
ﬁlters were exposed to X-ray ﬁlms and the intensity of the
bands quantiﬁed by Instant Imager (Packard Instruments,
Downers, IL, USA).
2.7. Statistical Methods. Analysis of the results from animal
studies was performed according the test on equality of
proportion by STATA program. Statistical evaluation of the
in vitro data was performed by the analysis of variance model
(ANOVA) with Tukey-Kramer adjustment for multiple com-
parisons, using the SAS software, version 9.1 (SAS Institute,
Cary, NC, USA). A P-value of <0.05 was considered as
signiﬁcant.
3. Results
3.1. Induction of Angioproliferative Lesions by FGF-2 Is
Associated with Bcl-2 Expression, and Both Are Enhanced by
Tat. Initial experiments investigated FGF-2 or Tat eﬀects on
Bcl-2 expression in vivo.
Our previous work tested the dose response eﬀects that
FGF-2 or Tat (0.1–100μg) has on the induction of histo-
logical features characterizing KS lesions in vivo [3, 4, 24].
Starting from those ﬁndings, we employed the Tat and/or
FGF-2 concentrations particularly eﬀective at promoting the
development of macroscopic KS-like lesions in mice.
Speciﬁcally, nude mice were injected with 1μg of FGF-
2 and/or 10μg of Tat. Control animals were inoculated with
the protein suspension buﬀer (PBS-0.1% BSA). After 7days,
mice were sacriﬁced and the sites of injection were examined
for the presence of angioproliferative lesions [3, 4]. Tissue
samples were excised and processed for histology and Bcl-2
immuno-histochemistry.
As shown in Figure 1, FGF-2 injection resulted in
the development of macroscopic angioproliferative KS-like
lesions. Speciﬁcally, 19 out of the 43 mice injected with
FGF-2 (=44%, P<0.001) developed KS-like lesions. This
was associated with the appearance of spindle-shaped cells
(Figure 1(a)), which are the histological hallmark of human
KS lesions [1], and with the induction of Bcl-2 expression
(Figure 1(b)). In particular, 32% (range 19–49) of the cells
present in the lesions were positive for Bcl-2.
Noteworthy, the simultaneous inoculation of FGF-2 and
Tat further increased both lesion development and Bcl-2
expression. In particular, out of the 31 mice injected with
combined FGF-2 and Tat, 22 (=71%, P < 0.05) developed
macroscopic lesions (Figure 1(c)), in which 47% (range 22–
67) of the cells were Bcl-2 positive (Figure 1(d)).
In contrast, none of the 17 mice injected with Tat
alone, and none of the 70 mice injected with the proteinInternational Journal of Vascular Medicine 5
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Figure 3: Eﬀect of FGF-2 and Tat on human endothelial cell anoikis. HUVECs were seeded onto poly- (HEMA)-coated plates and incubated
for 6h with FGF-2 (1 or 10ng/mL) and/or Tat (10ng/mL), controlled by their dilution buﬀer (PBS-0.1% BSA). HUVECs plated onto gelatin
were the negative control for apoptosis. In (a) are the results from the ELISA test determining the amount of nucleosomes in HUVECs
cytoplasm. The mean OD readings from 4 independent experiments (+SD) are presented. In (b) HUVECs apoptosis was evaluated by
TUNEL test. The mean percentage (+SD) of apoptotic cells was determined from 4 high-power ﬁelds (40X magniﬁcation) of 3 independent
experiments.
suspension buﬀer (PBS-0.1% BSA), developed macroscopic
lesions (Figures 1(e) and 1(g), resp.). For both experimental
conditions, Bcl-2 was not expressed at the sites of injection
(Figures 1(f) and 1(h),r e s p . ) .
To conﬁrm these in vivo results, the eﬀects of FGF-
2 and Tat on Bcl-2 expression were evaluated in cultured
human primary endothelial cells. To this end, HUVECs
were exposed for 24 hours to FGF-2 and/or Tat (controlled
by their suspension buﬀer), and Bcl-2 protein levels were
examined by Western blot analysis. As shown in Figure 2,
FGF-2 increased Bcl-2 protein expression, while Tat alone
had no eﬀect. However, when Tat was combined with FGF-2,
Bcl-2 protein levels further increased, conﬁrming the in vivo
data.
3.2. FGF-2 and Tat Protect Nonadherent Endothelial Cells
fromApoptosisviatheUpregulationofBcl-2Expression. Bcl-2
can protect endothelial cells from anoikis, the process where
adherent cells die when they lose contact with the ECM
[25, 26].
In view of our invivo andinvitroresults,additional work
was performed in order to evaluate FGF-2 or Tat eﬀect on
endothelial cell anoikis. To this end we seeded HUVECs onto
plates coated with poly- (HEMA), a compound preventing
cellular adhesion [23]. Then, we incubated the cells for
6h with FGF-2, Tat, or their suspension buﬀer. The entity
of cell death was determined by measuring, in HUVECs
cytoplasm, the content of nucleosomes, histone complex of
low-molecular-weight DNA fragments resulting from the
cleavage of apoptotic cell genome [27]. Adherent HUVECs
plated onto gelatin were the negative control for cell death
[25, 26].
As expected, HUVECs did not adhere onto poly-
(HEMA)-coated surfaces, and this was followed by a dra-
matic increase of nucleosome content in the cytoplasm of
nonadherent, as compared to adherent, HUVECs (P<
0.0001) (Figure 3(a)). Noteworthy, exposure of nonadherent
HUVECs to 1 or 10ng/mL FGF-2 reduced the amount of
cytoplasmic nucleosomes by 30% and 50%, respectively (P<
0.0001) (Figure 3(a)). Although Tat alone had no eﬀect,
when it was combined with 1ng/mL of FGF-2, it decreased
the amount of cytoplasmic nucleosomes to levels as found in
HUVECs treated with 10ng/mL FGF-2 (Figure 3(a)). Thus,
Tat increased FGF-2 capability of rescuing endothelial cell
apoptosis (P = 0.0102).
The TUNELassayconﬁrmedtheseresults.Speciﬁcally,in
nonadherent conditions, 1ng/mL of FGF-2 diminished the
numberofapoptoticHUVECsby55%whenemployedalone
(P = 0.0490) and by 80% when combined with 10ng/mL of
Tat (P = 0.0025) (Figure 3(b)).
Toinvestigatewhethertheincreaseofendothelialcellsur-
vival promoted by FGF-2 and Tat in nonadherent conditions
was accompanied by a modulation of Bcl-2 expression, Bcl-2
mRNA levels were evaluated in HUVECs under the diﬀerent
experimental conditions described above.
Results from RT-PCR assays indicated that Bcl-2 mRNA
levels decreased by −53% in nonadherent HUVECs, as
compared to the adherent control (P = 0.0396) (Figure 4).
When nonadherent HUVECs were exposed to 10ng/mL of
FGF-2, Bcl-2 mRNA expression was rescued to levels as
expressed by adherent HUVECs (P = 0.05) (Figure 4).
AlthoughTatalonehadnoeﬀect,whenitwascombinedwith
1ng/mL of FGF-2, the expression of Bcl-2 wasrestoredto the
levelsdetectedinadherentHUVECs(P = 0.0480)(Figure 4).6 International Journal of Vascular Medicine
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Figure 4: Protection of human endothelial cells from anoikis by
FGF-2 alone or combined with Tat parallels the up-regulation
of Bcl-2 expression. HUVECs were treated as described in the
legend of Figure 2. Total RNA was extracted from the cells, and
the Bcl-2 mRNA levels were analyzed by a housekeeping gene
normalized RT-PCR assay. In the upper panel is the Southern
blot hybridization of PCR products from a representative RT-
PCR experiment performed with primers speciﬁc for Bcl-2. In the
central panel is the β-actin RT-PCR ampliﬁcation of the samples,
showing that normalization of cDNA content resulted in β-actin
PCR bands of identical size. In the lower panel is the quantiﬁcation
of Bcl-2 hybridization bands by Instant Imager from 3 independent
experiments (average +SD).
4. Discussion
In healthy tissues, undesired angiogenesis is switched oﬀ
through the induction of endothelial cell apoptosis [25, 28].
This can be triggered by conditions, such as the lack of
angiogenic growth factors, or the inhibition of endothelial
celladhesionontotheECM,whichdownregulateendothelial
cell expression of antiapoptotic molecules [25, 28].
Among the latter, Bcl-2 is very eﬀective at favouring
the angiogenic process. In particular, Bcl-2 is overexpressed
by endothelial cells of the newly formed blood vessels
nourishing the growing tumor [29, 30].
In agreement with the fact that Bcl-2 expression can
lead to inappropriate endothelial cell survival and abnormal
angiogenesis [25, 28], clinical evidence suggests that the
deregulation of Bcl-2 expression could play a role in the
maintenance and progression of KS. In fact, Bcl-2 protein
levels augment in late-stage, as compared to early-stage, KS
lesions, and this parallels a decrease in vascular cell apoptosis
[8–12].
AroleforBcl-2inKSprogressionissupportedalsobythe
eﬃcacy of the Bcl-2 inhibitor paclitaxel in KS patients [31],
conﬁrming previous work performed with animal models of
KS [32].
Here, we evaluated whether FGF-2 or HIV-1 Tat, two key
AIDS-KS pathogenetic factors, could aﬀect Bcl-2 expression
in vivo and in vitro.
Results indicate that FGF-2 injection into mice results
in the induction of Bcl-2 expression and that this associates
with the development of angioproliferative, KS-like lesions.
Regarding Tat, it has no eﬀects on Bcl-2 expression when
present alone. Tat protein is known to enter cells and activate
the expression of cellular genes [6]. In particular, Tat was
shown to up-regulate Bcl-2 expression by monocytes, albeit
at higher concentrations than the ones we used here [33].
However, the possibility that in our experimental model Tat
could directly activate Bcl-2 expression is excluded by our
results indicating that Tat alone is not capable of promoting
KS-like lesions in mice, rescuing endothelial cell apoptosis
or inducing Bcl-2 expression by these cells. The contrasting
data that others obtained in monocytes could depend on
the diﬀerent cell type they utilized. The fact that Tat eﬀects
are cell-type dependent is strongly supported by previous
ﬁndings indicating that Tat promotes apoptosis in other cell
systems [34–39].
Incontrast,whenTatiscombinedwithFGF-2,itstrongly
enhances FGF-2 eﬀects on Bcl-2, this paralleling a dramatic
increase in the formation of angioproliferative lesions in
mice.
These ﬁndings are consistent with all the other activities
that Tat exerts on endothelial cells, which require FGF-2
presence in order to respond to Tat either in vitro or in vivo
[3, 4, 7]. In this regard, Tat and FGF-2 synergy is likely to
depend on FGF-2 capability of inducing the expression of
the αvβ3 and α5β1 integrins, which, in turn, function as Tat
receptors [3, 4, 7, 40]. On the other side, Tat can maintain
FGF-2 into a highly active and readily available form, thus
amplifying its biological eﬀects [7].
Previousstudiesindicatedthatthecross-talkbetweenthe
integrins and growth factor receptors triggers a signalling
cascade which is relevant for endothelial cell survival and
growth [25, 28]. In this regard, it has to be reminded that
signalling pathways leading to endothelial cell survival are
activated upon Tat binding to the integrins, being further
enhanced when FGF-2 is present in the environment [41]. In
this context, our previous work indicated that induction of
KS-like lesions by combined FGF-2 and Tat is reproduced by
combined FGF-2 and the integrin-binding Tat RGD peptide
(Tat 65–80), but not by mutated Tat KGE peptide [4].
In agreement with these ﬁndings, here we have reported
that the induction of Bcl-2 expression by FGF-2 and Tat
can prevent the death of endothelial cells resulting from the
inhibition of their adhesive interaction with the ECM.International Journal of Vascular Medicine 7
Altogether, these results suggest a pathway for Bcl-2
induction and a molecular mechanism by which the simul-
taneous presence of Tat and FGF-2 could promote KS main-
tenanceandprogressioninHIV-1-infectedindividuals.Since
Tat and FGF-2 are expressed in AIDS-KS lesions together
with Bcl-2 [1, 3], these ﬁndings appear to be of biological
relevance.
Finally, as Bcl-2 diverts vascular cells from apoptosis and
prolongs their survival [21, 29, 30, 42], its expression in
advanced KS, coupled with a deregulated cellular prolifera-
tion by HIV, HHV8, and cellular factors [1, 2], may result in
KS maintenance and/or the progression of the early angio-
hyperplastic KS lesions into a true sarcoma. This hypothesis
is supported by our recent observation that both FGF-2 and
Tat can increase in KS cells the activity of the telomerase, an
enzyme allowing cells to escape replicative senescence and to
proliferate indeﬁnitely [43, 44].
5. Conclusions
Our results indicate that FGF-2 and HIV-1 Tat synergize
at inducing Bcl-2 expression and that this is accompanied
by the inappropriate survival of endothelial cells and by
the development of angioproliferative lesions. These ﬁndings
suggest a molecular mechanism for the deregulated Bcl-2
expression observed in AIDS-KS lesions and conﬁrm that
Bcl-2 may represent a key target for therapeutic intervention
of KS.
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